Method for the treatment of hypercholesterolemia
US 9,610,273, US 9,668,999, AU2014202312, CA2850999, CA2963383, EA027148, EP2937084, HK1210590, I-622384, JP6263707, KR10-1647549, NZ624269, MY-170067-A, PH1-2014-000244
Anti-obesity potential of Calebin A
US 8,933,121, US 9,328,330, AU2012366253, AU2014203122, CA2857543, JP6374716, KR10-1702702, NZ614076, NZ715053, RU2543334, SG192695, ZA2013/05918, ZL201280012577.3
Compositions and method for the protection of articular cartilage
US 9,220,703, AU2014201769, CA2935898, EP2893926, JP6142446, KR10-1685263, KR10-1685333, MY-175867-A, NZ622909, PH1-2016-501138, SG11201605336Y
Calebin A for hepatic steatosis
US 9,737,502, CA2893321, IDP000067993, JP6336943, KR10-1763474, MY-182000-A, PH1-2015-000188, RU2643297, SG10201503805X
Synthesis of calebin A and its biologically active analogs
US 9,365,486, AU2014203764, CA2858126, EA027726, EP2963007, HK1217689, JP6490927, KR10-1629561, NZ627247
Calebin A for osteoporosis
US 9,539,232; CA2941050; RU2653103
Calebin A for use in the treatment of inflammation and obesity
EP2663185, HK1190874
Use of calebin A to protect mammalian articular cartilage from pathological damage
EA027614
Calebin A for articular cartilage
HK1210028
Calebin A and its effect on hypercholesterolemia
IDP000064827
Calebin A for inducing lipolysis
EP3085370